论文部分内容阅读
[目的]评价放射性核素89SrCl2联合帕米膦酸二钠治疗前列腺癌骨转移的疗效。[方法]46例前列腺癌骨转移并伴有不同程度骨痛患者,给予89SrCl2静脉注射联合帕米膦酸二钠静点治疗,观察其止痛效果、骨转移灶的变化、前列腺特异性抗原(PSA)及毒副反应等。[结果]骨痛症状的止痛总有效率分别为91.3%(42/46),骨转移病灶消失与减少率为69.6%(32/46),同时患者PSA有不同程度的下降,均未发现严重毒副反应。[结论]89SrCl2联合帕米膦酸二钠对前列腺癌骨转移止痛效果明显,同时对其转移灶有治疗作用,值得应用与推广。
[Objective] To evaluate the efficacy of 89SrCl2 combined with pamidronate in the treatment of bone metastasis of prostate cancer. [Methods] Forty-six patients with bone metastasis of prostate cancer accompanied with varying degrees of bone pain were given 89SrCl2 intravenous injection combined with pamidronate disodium static point treatment, analgesic effect, bone metastasis, PSA ) And toxic side effects. [Results] The total effective rates of analgesia of bone pain were 91.3% (42/46) respectively. The disappearance and reduction rate of bone metastases were 69.6% (32/46). At the same time, the patients’ PSA decreased to some extent, Toxic reaction. [Conclusion] 89SrCl2 combined with pamidronate disodium has obvious analgesic effects on bone metastasis of prostate cancer, meanwhile, it has a therapeutic effect on metastases and deserves application and promotion.